We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Single Rapid Test Detects Known and Unknown Pathogens

By LabMedica International staff writers
Posted on 10 Nov 2014
Diagnostic technology developed for rapid detection of pathogens in the wounds of soldiers has been licensed to a private company that intends to use it to create new medical laboratory tests.

The Lawrence Livermore Microbial Detection Array (LLMDA) is designed to improve on two pathogen identification techniques: Polymerase chain reaction (PCR) analysis and DNA sequencing. More...
PCR diagnostic techniques can process no more than 50 DNA signatures at one time and the likelihood of discovering new species are low with PCR. The new technology is capable of identifying thousands of bacteria and viruses in a single test.

Scientists at the Lawrence Livermore National Laboratory (LLNL; Livermore, CA, USA) developed the LLMDA. The process begins by purifying DNA or ribonucleic acid (RNA) from a blood or stool sample. The purified DNA or RNA is labeled with a fluorescent dye, and then pipetted onto the microarray which sits on top of an incubator heated to 42 °C. The microarray contains nearly 400,000 probes arranged in a checkerboard pattern on a 2.5 × 7.5-cm glass slide. Scientists examine these probes with a fluorescent scanner and analysis software. The microarray’s checkerboard has several dozen squares for each of the thousands of organisms sequenced to date. That allows it to simultaneously examine multiple regions from each organism.

From a study that evaluated 124 wound samples from 44 soldiers injured in Iraq and Afghanistan using LLDMA, the scientists found certain bacteria, such as Pseudomonas species and Acinetobacter baumannii, which are common hospital-related infections, to be associated with wounds that did not heal successfully. Bacteria often related to the gastrointestinal system, such as Escherichia coli and Bacteroides species, were also often found in wounds that did heal successfully. The test was able to detect within 24 hours any virus or bacteria that has been sequenced and included among the array's probes.

The LLNL scientists are already building on the capacity of this microbial array. They are currently testing a next-generation LLMDA that contains 2.1 million probes representing about 178,000 sequences from 5,700 viruses and 785,000 sequences from thousands of bacteria. The new version also includes about 237,000 sequences from hundreds of fungi and about 202,000 sequences from 75 protozoa. Lawrence Livermore National Laboratory has licensed its microbial detection array technology to MOgene LC (St. Louis, MO, USA).

Related Links:
Lawrence Livermore National Laboratory
MOgene LC 



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
PSA Assay
CanAg PSA EIA
New
Silver Member
Quality Control Material
Multichem ID-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.